Virus Like Particles

ALL Virus Like Particles

Filter By

Product Type

Product Category

Target Pathogen

Product Target

Application

Ebola Virus like particles (HA-EBOV) Sudan (Genebank: YP_138523.1)

Ebola Virus like particles (HA-EBOV) Sudan (Genebank: YP_138523.1) A novel rapid hybrid alpha-pseudovirus for Ebolaviruses (EBOV) (HA-EBOV) that are available for your initial testing from the Sudan Ebola strain (Genebank: YP_138523.1). These pseudoviruses are BSL2 safe and ready to use for studying viral entry. HAEBOV particles are pseudoviruses assembled from the structural proteins of the filovirus glycoprotein (GP), VP40 matrix protein, and the Nucleoprotein (NP) and package an alphaviral vector for reporter gene expression. The alpha-pseudoviruses are single-cycle viruses with self-replicating RNA for rapid quantification of neutralizing antibodies and entry-inhibiting drugs. Size:

1X concentrated 25 x 200 µL ~100 wells/96 well plate

Reporter: Available with Firefly luciferase, GFP, or RFP Formulation & Storage: Available upon request. Store at -80°C. Applications

Rapid NiV pseudovirus transduction of target cells for viral entry and functional studies
Anti-NiV drug screening
Anti-NiV neutralizing antibody screening

Intended for research use only, not for human, therapeutic, or diagnostic applications.

Price:

$4,305.00

Ebola Virus like particles (HA-EBOV) Zaire (Genebank: KJ660346.2)

Ebola Virus like particles (HA-EBOV) Zaire (Genebank: KJ660346.2) A novel rapid hybrid alpha-pseudovirus for Ebolaviruses (EBOV) (HA-EBOV) from the Zaire strain that are available for your initial testing. These pseudoviruses are BSL2 safe and ready to use for studying viral entry. HAEBOV particles are pseudoviruses assembled from the structural proteins of the filovirus glycoprotein (GP), VP40 matrix protein, and the Nucleoprotein (NP) and package an alphaviral vector for reporter gene expression. The alpha-pseudoviruses are single-cycle viruses with self-replicating RNA for rapid quantification of neutralizing antibodies and entry-inhibiting drugs. Size:

1X concentrated 25 x 200 µL ~100 wells/96 well plate

Reporter: Available with Firefly luciferase, GFP, or RFP Formulation & Storage: Available upon request. Store at -80°C. Applications

Rapid NiV pseudovirus transduction of target cells for viral entry and functional studies
Anti-NiV drug screening
Anti-NiV neutralizing antibody screening

Intended for research use only, not for human, therapeutic, or diagnostic applications.

Price:

$4,100.00

Ebola virus-like particles (EBOV VLP) (Zaire)

Virus-like Particles (VLP’s) expressing recombinant Ebola virus (EBOV) glycoprotein (GP), nucleoprotein (NP), and matrix protein (VP40). These VLP’s mimic Ebola virus but do not contain genetic material, thus are not infectious and make an ideal candidate as a vaccine and tool to enhance filovirus research.

Formulation & Storage: Supplied in PBS (supplemented with arginine and glutamic acid). Store at 2-3 weeks at -20°C, -80°C long term. Subaliquoting is recommended to avoid repeated freeze/thaw cycles.
Pathogen Strain: Zaire
Purification: Column chromatography
Expression: SF9 cells
Please note: After thawing, VLP’s tend to sediment to bottom of the tube and appear as aggregate pellet. Resuspend by gentle vortexing or pipetting up and down
Certificate of analysis: A hardcopy of datasheet is sent along with the products. Please refer to it for detailed information.

Please email products@integratedbiotherapeutics.com for lot specific information for ‘Titer’ and ‘Usage’.

Price:

$723.00

HIV Virus like particle (Human Immunodeficiency Virus)

HIV Virus like particle (VLP’s) expressing recombinant structural proteins Safe for use in BSL-2 facilities. Size:

1X concentrated 25 x 200 µL ~100 wells/96 well plate

Reporter: Available with Firefly luciferase, GFP, or RFP Formulation & Storage: Available upon request. Store at -80°C. Intended for research use only, not for human, therapeutic, or diagnostic applications.

Price:

$4,100.00

Influenza H5 Pseudovirus

Lentivirus vector pseudotyped with Influenza H5 hemagglutinin. This pseudovirus is derived from a third-generation lentiviral vector. It is replication-incompetent, non-toxic, and must be handled under BSL-2 conditions. Infectivity and neutralization of infectivity can be measured by luciferase activity.

Formulation & Storage: Supplied in a conservation solution containing culture media with FBS. Store at -80°C, avoid freeze/thaw cycles.
Titer Estimate*: Approximatively 5 x 10^4 RLU/µL.
Usage Estimates*: Use 1 µL to obtain an RLU to background ratio of 10^3. A volume of 100 µL can be used to perform 100 reactions or 1 x 96-well plate.
Reporter: Luciferase

Please email products@integratedbiotherapeutics.com for lot specific information for ‘Titer’ and ‘Usage’.

Price:

$2,994.00

Influenza H7 Pseudovirus

Lentivirus vector pseudotyped with Influenza H7 hemagglutinin. This pseudovirus is derived from a third-generation lentiviral vector. It is replication-incompetent, non-toxic, and must be handled under BSL-2 conditions. Infectivity and neutralization of infectivity can be measured by luciferase activity.

Formulation & Storage: Supplied in a conservation solution containing culture media with FBS. Store at -80°C, avoid freeze/thaw cycles.
Titer Estimate*: Approximatively 1 x 10^5 RLU/µL
Usage Estimates*: Use 1 µL to obtain an RLU to background ratio of 10^3. A volume of 100 µL can be used to perform 100 reactions or 1 x 96-well plate.
Reporter: Luciferase

Please email products@integratedbiotherapeutics.com for lot specific information for ‘Titer’ and ‘Usage’.

Price:

$2,994.00

Marburg virus like particles (HA-MARV) MARV001 Isolate (Genebank: OL702894.1)

Marburg virus like particles (HA-MARV) MARV001 Isolate (Genebank: OL702894.1) A novel rapid hybrid alpha-pseudovirus for Marburg (MARV) (HA-MARV) MARV001 Isolate that is available for your initial testing. These pseudoviruses are BSL-2 safe and ready to use for studying viral entry. HA-MARV particles are pseudoviruses assembled from the structural proteins of the filovirus glycoprotein (GP), VP40 matrix protein, and the Nucleoprotein (NP) and package an alphaviral vector for reporter gene expression. The alpha-pseudoviruses are single-cycle viruses with self-replicating RNA for rapid quantification of neutralizing antibodies and entryinhibiting drugs. Size:

1X concentrated 25 x 200 µL ~100 wells/96 well plate

Reporter: Available with Firefly luciferase, GFP, or RFP Formulation & Storage: Available upon request. Store at -80°C. Applications

Marburg pseudovirus transduction of target cells for viral entry and functional studies
Rapid Anti-Marburg drug screening
Rapid Anti-Marburg neutralizing antibody

Intended for research use only, not for human, therapeutic, or diagnostic applications.

Price:

$6,305.00

Marburg-Musoke virus-like particles (MMARV VLP)

Virus-like Particles (VLP’s) expressing recombinant Marburg (MARV) glycoprotein (GP), nucleoprotein (NP), and matrix protein (VP40). Since these VLP’s mimic MARV (Musoke) virus but do not contain genetic material, thus are not infectious making an ideal candidate as a vaccine and a tool to enhance filovirus research.

Formulation & Storage: Supplied in PBS (supplemented with arginine and glutamic acid). Store at 2-3 weeks at -20°C, -80°C long term. Subaliquoting is recommended to avoid repeated freeze/thaw cycles.
Pathogen Strain: Musoke
Purification: Column chromatography
Expression: SF9 cells
Please note: After thawing, VLP’s tend to sediment to the bottom of the tube and appear as aggregate pellet. VLP’s can be resuspended by gentle vortexing or by pipetting up and down, before use. Also, subaliquoting is recommended to avoid repeated freeze/thaw cycles.
Certificate of analysis: A hardcopy of datasheet is sent along with the products. Please refer to it for detailed information.

Price:

$723.00

Middle Eastern Respiratory Syndrome Corona Virus 2 (MERS-CoV-2) Virus Like Particle, Wild Type

Middle Eastern Respiratory Syndrome Corona Virus 2 (MERS-CoV-2) Virus Like Particle, Wild Type The hybrid alpha-pseudovirus for MERS-CoV-2 (Ha-MERSCoV-2) is a newly developed MARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)pseudoviruses, Ha-MERS-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of MERS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Size:

60X concentrated 5 x 100 µL
1x Conc. 25 x 200uL (~100 wells)

Reporter: Available with Firefly luciferase, GFP, or RFP Formulation & Storage: Store at -80°C. Applications:

Screening and quantification of anti-coronavirusneutralizing antibodies
Anti-coronavirus drug screening
Quantification of viral mutants’ infectivity
Identification of host co-factors and restriction factors of coronaviruses

Intended for research use only, not for human, therapeutic, or diagnostic applications.

Price:

Nipah Virus-like particles (HA-NiV)

Nipah Virus-like particles (HA-NiV) A novel rapid hybrid alpha-pseudovirus for Nipah virus (HA-NiV). HA-NiV particles are pseudoviruses assembled from the structural proteins of the Nipah virus, Fusion (F), Glycoprotein (G), Matrix (M), and Nucleocapsid (N) proteins and package an alphaviral vector for reporter gene expression. The alphapseudoviruses are single-cycle viruses with self-replicating RNA for rapid quantification of neutralizing antibodies and entry-inhibiting drugs. These pseudoviruses are BSL-2 safe and ready to use for studying viral entry. Size:

1X concentrated 25 x 200 µL ~100 wells/96 well plate

Reporter: Available with Firefly luciferase, GFP, or RFP Formulation & Storage: Store at -80°C. Applications

Rapid NiV pseudovirus transduction of target cells for viral entry and functional studies
Anti-NiV drug screening
Anti-NiV neutralizing antibody screening

Intended for research use only, not for human, therapeutic, or diagnostic applications.

Price:

$4,520.00

SARS-CoV-2 Virus Like Particles (Ha-CoV2) Delta Plus (AY.2)

SARS-CoV-2, Virus Like Particles (Ha-CoV2) Delta Plus (AY.2) The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Spike Mutations: Spike T19R, Spike V70F, Spiked del157/158, Spike A222V, Spike K417N, Spike L452R, Spike T478K, Spike D614G, Spike P681R, Spike D950N Size:

25 X 200 µL ~100 wells/96 well plate
60x Conc. 5 x 100 µL

Reporter: Available with Firefly luciferase, GFP, or RFP Formulation & Storage: Store at -80°C. Intended for research use only, not for human, therapeutic, or diagnostic applications.

Price:

Price range: $1,490.00 through $2,350.00

SARS-CoV-2, Virus Like Particles (Alpha (B.1.1.7))

SARS-CoV-2 Virus Like Particles (Alpha (B.1.1.7)) The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Spike mutations: Spike A570D, Spike D614G, Spike D1118H, Spike H69del, Spike N501Y, Spike P681H, Spike S982A, Spike T716I, Spike V70del, Spike Y145del Size:

25 X 200 µL ~100 wells/96 well plate
60x Conc. 5 x 100 µL

Reporter: Available with Firefly luciferase, GFP, or RFP Formulation & Storage: Available upon request. Store at -80°C. Intended for research use only, not for human, therapeutic, or diagnostic applications.

Price:

Price range: $1,643.00 through $2,591.00

SARS-CoV-2, Virus Like Particles (B.1.1.207)

Virus Like Particles for SARS-CoV-2 strain: B.1.1.207 The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2, Virus Like Particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Spike mutations: Spike D614G, Spike E484K, Spike P681H Size:

25 X 200 µL ~100 wells/96 well plate
60x Conc. 5 x 100 µL

Price:

Price range: $1,643.00 through $2,591.00

SARS-CoV-2, Virus Like Particles (D614G Single AA Mutant)

The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Spike mutations: Spike D614G Size(s):

25 X 200 µL ~100 wells/96 well plate
60x Conc. 5 x 100 µL

Price:

Price range: $1,643.00 through $2,591.00

SARS-CoV-2, Virus Like Particles (Ha-CoV2) (B.1.1.298)

SARS-CoV-2, Virus Like Particles (Ha-CoV2) (B.1.1.298) The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Spike Mutations: Spike D614G, Spike H69del, Spike I692V, Spike M1229I, Spike V70del, Spike Y453F Size:

25 X 200 µL ~100 wells/96 well plate
60x Conc. 5 x 100 µL

Reporter: Available with Firefly luciferase, GFP, or RFP Formulation & Storage: Store at -80°C. Intended for research use only, not for human, therapeutic, or diagnostic applications.

Price:

Price range: $1,643.00 through $2,591.00

SARS-CoV-2, Virus Like Particles (Ha-CoV2) (B.1.2)

SARS-CoV-2, Virus Like Particles (Ha-CoV2) (B.1.2) The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Spike Mutations: Spike D614G, Spike E484K, Spike G446V, Spike Y453F Size:

25 X 200 µL ~100 wells/96 well plate
60x Conc. 5 x 100 µL

Reporter: Available with Firefly luciferase, GFP, or RFP Formulation & Storage: Store at -80°C. Intended for research use only, not for human, therapeutic, or diagnostic applications.

Price:

Price range: $1,643.00 through $2,591.00

SARS-CoV-2, Virus Like Particles (Ha-CoV2) (B.1.258)

SARS-CoV-2, Virus Like Particles (Ha-CoV2) (B.1.258) The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Spike Mutations: Spike D614G, Spike H69del, Spike N439K, Spike V70del Size:

25 X 200 µL ~100 wells/96 well plate
60x Conc. 5 x 100 µL

Reporter: Available with Firefly luciferase, GFP, or RFP Formulation & Storage: Store at -80°C. Intended for research use only, not for human, therapeutic, or diagnostic applications.

Price:

Price range: $1,490.00 through $2,350.00

SARS-CoV-2, Virus Like Particles (Ha-CoV2) (B.1.351)

SARS-CoV-2, Virus Like Particles (Ha-CoV2) (B.1.351) The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Spike Mutations: Spike A243del, Spike A701V, Spike D80A, Spike D215G, Spike D614G, Spike E484K, Spike K417N, Spike L242del, Spike L244del, Spike N501Y Size:

25 X 200 µL ~100 wells/96 well plate
60x Conc. 5 x 100 µL

Reporter: Available with Firefly luciferase, GFP, or RFP Formulation & Storage: Store at -80°C. Intended for research use only, not for human, therapeutic, or diagnostic applications.